Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation
Sustained response to treatment reduces fatigue in hepatitis C patients
Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4
Three-drug AbbVie combination safe and highly effective in treatment of post-transplant hepatitis C recurrence
Sofosbuvir for hepatitis C works well despite multiple negative predictive factors
Sofosbuvir + new GS-5816 NS5A inhibitor is effective against hepatitis C genotypes 1-6
BMS combination cures 90% of genotype 1b hepatitis C in 24 weeks
Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease
Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B
AbbVie 3-drug combination cures 92 to 96% of hepatitis C patients with cirrhosis
AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C
Sofosbuvir/ledipasvir co-formulation cures more than 90% of treatment-naive and retreated genotype 1 patients
Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis
European liver specialists recommend 'mix-and-match' approach to new hepatitis C drugs
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections
